This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dr. Joanna Horobin Joins Verastem As Chief Medical Officer

Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of Joanna Horobin, M.B., Ch.B., as Chief Medical Officer. Dr. Horobin was most recently the President of Syndax Pharmaceuticals, Inc. and has been responsible for the development and approval of multiple drugs over the course of her career.

“Joanna’s track record of execution across a broad range of products positions us well as we progress towards initiating a potential registration study of VS-6063 in mesothelioma mid-next year,” said Christoph Westphal, M.D., Ph.D., Chairman and CEO of Verastem.

Dr. Horobin has 30 years of pharmaceutical drug development experience. As President of Syndax, Dr. Horobin designed and implemented the Phase 2 clinical development of entinostat in metastatic breast and lung cancer.

“Dr. Horobin brings a great deal of successful experience in the design and execution of clinical development programs in oncology,” said Jose Baselga, M.D., Ph.D., Verastem Scientific Advisory Board.

Verastem has identified a specific genetic biomarker which it believes predicts sensitivity to the focal adhesion kinase inhibitors VS-6063 and VS-4718. Approximately 40-50% of mesothelioma patients lack this marker. The Verastem development team, led by Dr. Horobin, is designing a Phase 2 trial in this indication that, if successful, may allow for an accelerated approval.

“Verastem is moving quickly to translate the pioneering discoveries of Dr. Bob Weinberg to clinical products targeting cancer stem cells,” said Dr. Horobin. “I am excited to join the team and drive these programs forward. With three cancer stem cell-targeted candidates in development, Verastem is taking significant strides towards revolutionizing the standard of care in oncology.”

Dr. Horobin was VP, Oncology at Rhone-Poulenc Rorer (now Sanofi, NYSE: SNY) where she led the global oncology business, including the successful global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim). Previously, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®. Dr. Horobin received her medical degree from the University of Manchester, England.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs